EULAR recommendations for the management of large vessel vasculitis

Ann Rheum Dis. 2009 Mar;68(3):318-23. doi: 10.1136/ard.2008.088351. Epub 2008 Apr 15.

Abstract

Objectives: To develop European League Against Rheumatism (EULAR) recommendations for the management of large vessel vasculitis.

Methods: An expert group (10 rheumatologists, 3 nephrologists, 2 immunolgists, 2 internists representing 8 European countries and the USA, a clinical epidemiologist and a representative from a drug regulatory agency) identified 10 topics for a systematic literature search through a modified Delphi technique. In accordance with standardised EULAR operating procedures, recommendations were derived for the management of large vessel vasculitis. In the absence of evidence, recommendations were formulated on the basis of a consensus opinion.

Results: Seven recommendations were made relating to the assessment, investigation and treatment of patients with large vessel vasculitis. The strength of recommendations was restricted by the low level of evidence and EULAR standardised operating procedures.

Conclusions: On the basis of evidence and expert consensus, management recommendations for large vessel vasculitis have been formulated and are commended for use in everyday clinical practice.

Publication types

  • Consensus Development Conference

MeSH terms

  • Aspirin / therapeutic use
  • Drug Monitoring / methods
  • Drug Therapy, Combination
  • Evidence-Based Medicine
  • Giant Cell Arteritis / diagnosis
  • Giant Cell Arteritis / drug therapy
  • Glucocorticoids / therapeutic use
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Inflammation Mediators / metabolism
  • Takayasu Arteritis / diagnosis
  • Takayasu Arteritis / drug therapy
  • Vasculitis / diagnosis
  • Vasculitis / drug therapy*
  • Vasculitis / pathology

Substances

  • Glucocorticoids
  • Immunosuppressive Agents
  • Inflammation Mediators
  • Aspirin